Fate Therapeutics (FATE) Treasury Shares (2012 - 2013)

Fate Therapeutics (FATE) has 15 years of Treasury Shares data on file, last reported at $9.3 million in Q1 2026.

• Quarterly Treasury Shares rose 28.42% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 28.42% YoY) and the FY2025 annual result came in at $6.6 million, up 6.79% from the prior year.
• Treasury Shares rose to $9.3 million in Q1 2026, from $6.6 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $9.3 million in Q1 2026 to a low of $3.1 million in Q4 2023.
• A 5-year average of $5.5 million and a median of $5.9 million in 2022 frame the typical range for Treasury Shares.
• Annual changes were most pronounced in 2022 — Treasury Shares surged 284.99% — and 2023, when it plunged 47.72%.
• Tracing FATE's Treasury Shares over 5 years: stood at $5.9 million in 2022, then sank by 47.72% to $3.1 million in 2023, then surged by 102.74% to $6.2 million in 2024, then grew by 6.79% to $6.6 million in 2025, then surged by 40.02% to $9.3 million in 2026.
• The last three Treasury Shares figures came in at $9.3 million (Q1 2026), $6.6 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.